- Home
- CMPX vs VERV Comparison
CMPX vs VERV Comparison
Compare CMPX & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- VERV
- Stock Information
- Founded
- CMPX 2014
- VERV 2018
- Country
- CMPX United States
- VERV United States
- Employees
- CMPX N/A
- VERV N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- VERV Medicinal Chemicals and Botanical Products
- Sector
- CMPX Health Care
- VERV Health Care
- Exchange
- CMPX Nasdaq
- VERV Nasdaq
- Market Cap
- CMPX 408.6M
- VERV N/A
- IPO Year
- CMPX N/A
- VERV 2021
- Fundamental
- Price
- CMPX $1.95
- VERV $4.65
- Analyst Decision
- CMPX Strong Buy
- VERV Strong Buy
- Analyst Count
- CMPX 7
- VERV 5
- Target Price
- CMPX $12.43
- VERV $25.50
- AVG Volume (30 Days)
- CMPX 850.8K
- VERV 1.2M
- Earning Date
- CMPX 05-12-2025
- VERV 05-07-2025
- Dividend Yield
- CMPX N/A
- VERV N/A
- EPS Growth
- CMPX N/A
- VERV N/A
- EPS
- CMPX N/A
- VERV N/A
- Revenue
- CMPX $850,000.00
- VERV $32,332,000.00
- Revenue This Year
- CMPX $47.65
- VERV N/A
- Revenue Next Year
- CMPX $3,909.48
- VERV N/A
- P/E Ratio
- CMPX N/A
- VERV N/A
- Revenue Growth
- CMPX N/A
- VERV 174.98
- 52 Week Low
- CMPX $0.77
- VERV $4.31
- 52 Week High
- CMPX $4.08
- VERV $13.24
- Technical
- Relative Strength Index (RSI)
- CMPX 31.88
- VERV 35.67
- Support Level
- CMPX $2.18
- VERV $5.26
- Resistance Level
- CMPX $2.17
- VERV $5.99
- Average True Range (ATR)
- CMPX 0.16
- VERV 0.45
- MACD
- CMPX -0.03
- VERV -0.05
- Stochastic Oscillator
- CMPX 14.60
- VERV 4.79
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.